The awards they have received are:
- 2018 Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pain for up to $1.5 million.
- 2018 Phase II Small Business Innovative Research Grant (SBIR) from The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to develop efficacious and highly selective inhibitors of CYP26s for the topical treatment of ichthyosis for $1.5 million.
- 2019 Phase 1 STTR grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pruritus for up to $1.5 million.
Dermaxon is partnered with ASCEND innovation award winner Stephen Lodmell and has attended many ASCEND webinars in the past. Congratulations to the Dermaxon team on these notable accomplishments! For more information please visit the Dermaxon website here: https://dermaxon.com/.